Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Thursday, Needham analysts maintained a Hold rating on shares of Envista Holdings Corp . (NYSE: NYSE:NVST), a $3.54 billion dental products company, following the company’s fourth-quarter financial results, which surpassed consensus revenue and earnings expectations. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation, with analyst price targets ranging from $18 to $26. The dental product maker also provided revenue and earnings per share (EPS) guidance for 2025 that did not meet analyst predictions.
Envista Holdings reported a strong finish to the year, particularly noting a rapid improvement in its highest margin product category, dental implants. The company maintains a healthy financial position with a current ratio of 2.08, indicating strong liquidity. The company’s fastest-growing product, Spark, is anticipated to reach operational profitability in the second half of 2025. Despite these positive developments and a notable 30.5% stock price increase over the past six months, Needham analysts believe that the current financial projections do not suggest significant room for upward adjustments, leading them to maintain their Hold rating on the stock.
The company’s performance in the fourth quarter of 2024 was bolstered by better-than-expected sales and earnings. However, the 2025 guidance provided by management fell short of consensus estimates, which may have tempered analyst enthusiasm.
Envista Holdings is expected to offer more detailed insights into its growth and margin expectations during its upcoming Capital Markets Day on March 5, 2025. Investors and analysts alike are looking forward to this event for a clearer picture of the company’s long-term strategic plans and financial targets.
In summary, while Envista Holdings ended 2024 on a high note with strong product performance and earnings, Needham analysts have chosen to maintain a cautious stance on the stock until further clarity is provided at the upcoming Capital Markets Day event. For deeper insights into Envista’s financial health (rated as GOOD by InvestingPro), including additional ProTips and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro.
In other recent news, Envista Holdings has announced a stock repurchase program authorizing the buyback of up to $250 million of its outstanding common stock. This strategic decision by the company’s Board of Directors is a common practice among corporations aiming to return capital to shareholders and potentially reduce the number of shares outstanding. The timing and amount of repurchases will be determined by market conditions.
Meanwhile, Piper Sandler has raised the stock price target for Envista Holdings to $18, up from the previous $17, while maintaining a Neutral rating. The firm’s analyst, Jason Bednar, expects the company’s fourth-quarter results to slightly exceed expectations and anticipates further evidence of early progress in turnaround efforts. However, the recovery pace of Envista’s specialty business, accounting for 65% of its revenue, is expected to lag behind other areas of the dental industry.
On the other hand, Mizuho (NYSE:MFG) Securities has initiated coverage of Envista Holdings with an Underperform rating and a price target of $20.00. This rating reflects the firm’s cautious stance on the stock, considering the current market conditions and the company’s recent financial performance. The recent C-suite changes at Envista, including the appointment of new CEO Paul Keel, are believed to have laid the groundwork for potential EPS growth in 2025 and 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.